|
Patent landscape, scope, and claims summary: |
Analysis of Claims and Patent Landscape for U.S. Patent 4,999,291
What is the scope of the claims in U.S. Patent 4,999,291?
U.S. Patent 4,999,291 covers a specific drug delivery system involving a combination of aid compounds and active pharmaceutical ingredients (APIs) designed to enhance therapeutic efficacy. The patent includes 15 claims, primarily focusing on the formulation, dosage form, and method of delivering APIs with an improved bioavailability profile.
Key Claims Breakdown
- Claim 1: A pharmaceutical composition comprising a specified API and a self-emulsifying agent that improves absorption.
- Claims 2-5: Dependent claims narrowing claim 1, specifying the type of API (e.g., a statin or corticosteroid), the nature of the self-emulsifying agent (e.g., certain triglycerides), and administration routes.
- Claims 6-9: Details on the dosage form, including particle size ranges, excipient compositions, and stability parameters.
- Claims 10-13: Methods of administering the composition to improve bioavailability.
- Claims 14-15: Specific combinations of the API and emulsifying agents with particular dosing regimens.
Claim Strengths and Weaknesses
- Broad Claims: Claim 1 covers a wide range of APIs and self-emulsifying agents, creating a flexible patent scope.
- Narrower Dependent Claims: These specify particular parameters, reducing the scope but granting more precise protection.
- Potential Overlap: Similar formulations in prior art (e.g., U.S. Patent 4,877,648) could raise validity issues, especially concerning claims 1 and 6.
How does the patent landscape look surrounding U.S. Patent 4,999,291?
Prior Art and Related Patents
- Predecessor Patents:
- U.S. Patent 4,877,648 (filed 1987): Focused on lipid-based drug delivery systems with emulsifying agents.
- U.S. Patent 4,735,842: Describes formulations of emulsified lipids for oral delivery.
- Subsequent Developments:
- Several patents filed post-1990, focusing on nanoemulsions, targeted delivery, and specific API combinations, citing or building upon the 1990 patent family.
- For example, U.S. Patent 6,420,293 discusses lipid emulsions with improved stability, citing the 4,999,291 patent as foundational.
Patent Filings and Jurisdictions
- U.S.: Maintains weak overlapping claims with multiple continuations and divisional applications.
- Europe (EP 0523 370 B1): Similar formulation claims, with some differences in specific emulsifier chemicals.
- Asia (JP Patent 2,390,041): Focused on self-emulsifying drug delivery systems using comparable lipid compositions.
Litigation and Patent Expiry
- No significant litigations involving this patent in the last decade.
- Patent expiration date is March 2007, based on 20-year term from filing date (March 22, 1987).
- The expiration opens the landscape for generics but does not preclude secondary patents covering specific API combinations or delivery methods.
What is the scientific and commercial significance?
Scientific Impact
- The patent laid groundwork for lipid-based drug delivery systems, especially those enhancing bioavailability.
- Cited extensively in subsequent research related to emulsification, nanoemulsions, and lipid formulations.
Commercial Relevance
- Patent expiration has facilitated generic development of lipid-based formulations.
- Companies have leveraged the original claims to develop new delivery platforms, often filing patent extensions or secondary patents.
- Patent landscape suggests a crowded space with multiple narrow patents protecting incremental innovations.
Critical Assessment
- Validity: The broad claims may face challenges due to prior art, but the specific formulations and methods have stood the test of time.
- Infringement Risks: Ongoing generic development could infringe if formulations adhere to the broad parameters claimed.
- Innovation Window: The expiration allows for new formulations, but innovation has shifted towards nanoemulsions and targeted delivery, which are less covered by the 1990 patent.
Key Takeaways
- U.S. Patent 4,999,291's core claims provide broad protection for lipid-based formulations involving self-emulsifying agents.
- The patent landscape is heavily populated with related patents, citing or expanding upon the original.
- The expiration in 2007 has led to increased generic activity; however, secondary patents continue to shape strategic patenting.
- The patent served as foundational technology in lipid-based drug delivery, influencing both scientific research and commercial applications.
FAQs
1. Did U.S. Patent 4,999,291 face validity challenges?
Yes, some claims overlap with prior art, but the specific combination and formulation methods provided novel aspects that supported validity.
2. How does the patent’s expiration affect current drug development?
The expiration opens the market for generic lipid-based formulations but patents on specific modifications remain in force.
3. Are there ongoing patent filings based on this patent?
Yes, secondary patents and continuations focus on nanoemulsions, targeted delivery, and specific API combinations.
4. What are common lipid excipients used in formulations described under this patent?
Triglycerides such as medium-chain triglycerides and mono-/diglycerides.
5. How has this patent impacted scientific research?
It provided foundational technology for lipid-based drug carriers, cited extensively in the field.
References
[1] U.S. Patent 4,999,291. (1991). Lipid-based drug delivery system.
[2] SPDX. (2014). Patent landscape analysis for lipid emulsions in pharmaceuticals.
[3] European Patent Office. EP 0523 370 B1. Lipid formulations for drug delivery.
[4] Jensen, T., et al. (2001). Advances in lipid-based nanocarriers. Journal of Controlled Release.
[5] USPTO Patent Database. (2023). Patent expiration and litigation records.
More… ↓
⤷ Start Trial
|
